{"id":542601,"date":"2021-05-10T22:58:01","date_gmt":"2021-05-10T22:58:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=542601"},"modified":"2021-05-10T22:58:01","modified_gmt":"2021-05-10T22:58:01","slug":"oncolytic-virus-cancer-therapy-pipeline-emerging-therapies-and-key-pharma-players-involved-by-delveinsight-cg-oncolgy-oncolytics-biotech-astellas-pharma-dnatrix-nouscom-immvira-pharma-others","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/oncolytic-virus-cancer-therapy-pipeline-emerging-therapies-and-key-pharma-players-involved-by-delveinsight-cg-oncolgy-oncolytics-biotech-astellas-pharma-dnatrix-nouscom-immvira-pharma-others_542601.html","title":{"rendered":"Oncolytic Virus Cancer Therapy Pipeline: Emerging Therapies and Key pharma players involved by DelveInsight | CG Oncolgy, Oncolytics Biotech, Astellas Pharma, DNAtrix, Nouscom, ImmVira Pharma, Others"},"content":{"rendered":"
\"Oncolytic<\/a><\/p>\n
\n
Oncolytic Virus Cancer Therapy Pipeline<\/div>\n<\/div>\n<\/div>\n

Oncolytic virus cancer therapies<\/strong> are the virus based therapeutic strategies that infect and destroy cancer cells, and therefore act as an in situ cancer vaccine by releasing tumor-specific antigens. Viruses such as myxoma virus or reovirus have inherent selectivity to tumor cells, while being nonpathogenic to healthy human cells. On the other hand, other OVs, including adenovirus, herpes simplex virus type-1 (HSV-1), and vesicular stomatitis virus (VSV), have been genetically engineered to function as vectors to boost anti-tumor immune responses. The therapeutic efficacy of Oncolytic viruses depends on two main modes of action: First, Oncolytic viruses can inhibit protein synthesis of tumor cells and destroy infected tumor cells by self-replication. After viral infection, Oncolytic viruses continue self-replication until the cell bursts; Second, Oncolytic viruses can recruit and activate tumor-infiltrating immune cells by releasing a large amount of tumor antigens and secreting cytokines.<\/p>\n

DelveInsight’s, “Oncolytic Virus Cancer Therapy Pipeline<\/a> Insight, 2021,”<\/strong> report provides comprehensive insights about 45+ companies and 85+ pipeline drugs in Oncolytic Virus Cancer Therapy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.<\/p>\n

 <\/p>\n

Request for Free Sample Report: https:\/\/www.delveinsight.com\/sample-request\/oncolytic-virus-cancer-therapy-pipeline-insight-2021<\/a><\/strong><\/p>\n

 <\/p>\n

Some of Oncolytic Virus Cancer Therapy Companies:<\/strong><\/p>\n